Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2009

Morphotek to Develop Antibodies to Validate Antigens Found by HGS

Morphotek to Develop Antibodies to Validate Antigens Found by HGS

Companies form partnership to develop antigens

  • Morphotek agreed to discover, develop, and commercialize mAbs targeting antigens discovered by Human Genome Services in the fields of oncology and immunology. Morphotek will be responsible for validating targets found in HGS genomic research, developing antibody candidates, and conducting preclinical proof-of-concept studies. Companies may choose to opt in to participate in further development and commercialization, with costs dependent on the individual situation.

    "The rapid commercialization of our late-stage compounds continues to be the priority focus of HGS," says H. Thomas Watkins, president and CEO of HGS. "At the same time, we also remain committed to advancing our earlier and mid-stage programs in development to ensure sustainable growth well into the future."

    In the past three years, HGS has identified approximately 50 therapeutic and diagnostic targets for further research and potential development through future collaborations such as the one with Morphotek, says the company.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »